Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Merck & Company (MRK – Research ...

Merck & Co has a lower P/E than the aggregate P/E of 26.97 of the Pharmaceuticals industry. Ideally, one might believe that ...

Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently signed with ...

Merck is a multi-national biopharmaceutical company, engaged in developing novel solutions for the prevention and treatment of diseases in people and animals. Merck offers medicines, vaccines ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

a global pharmaceutical company focusing on scientific and technological innovation, announced on March 25 that it has entered into an exclusive license agreement with United States-based Merck ...

Takeda Pharmaceutical Trading Up 0.8 % Shares of Takeda Pharmaceutical stock opened at $15.15 on Friday. Takeda Pharmaceutical Company Limited has a 1 year low of $12.58 and a 1 year high of $15. ...

It is a cancer drug her company discovered—one that has made her the face of a rising pharmaceutical star ... has shown favorable results versus Merck’s $29.5-billion-a-year cancer treatment ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Eton Pharmaceuticals, Inc., a specialty ...

Takeda Pharmaceutical Stock Up 0.2 % TAK stock opened at $15.20 on Monday. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The firm has a market ...